Author

Daniel Kaiser

Humboldt-Universität zu BerlinPrimary ORCID profile (0000-0002-9007-3160 · 7 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Daniel KaiseriD7 papers · Justus-Liebig-Universität Gießen

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 1 Assay:flow cytometry· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1

Frequent Co-Authors

Abdolreza Nazari· 1 shared Anamika Giri· 1 shared Andrea Sánchez PeñaiD· 1 shared Andy Roemhild· 1 shared Ashley M. JacobiiD· 1 shared C. Beltran-Mestres· 1 shared Christian M. Brommel· 1 shared Désirée J. WenderingiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

Abdolreza Nazari

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Clinical development of gene edited tacrolimus-resistant Treg (FKBP12KO-Treg) to enable simultaneous immunosuppression and support of immune regulation

Ghazaleh Zarrinrad, Lisa-Marie Burkhardt, C. Beltran-Mestres, Silvina Romero‐Suárez, Dimitrios L. Wagner, Stephan Schlickeiser, Maik Stein, Désirée J. Wendering, Iván Juky Carrera Diaz de la Cebosa, Lukas Ehlen, Frederik Hamm, Gavin Kurgan, Pawel Durek, Frederik Heinrich, Anamika Giri, , Leila Amini

This paper develops gene-edited tacrolimus-resistant Treg cells (FKBP12KO-Treg) for clinical use in transplant recipients, showing they maintain immunoregulatory function while resisting tacrolimus.

Molecular Therapy Advances · Apr 9, 2026Peer-reviewedImmunology